Moreno Evelyn V decreased its stake in Stryker Corporation (NYSE:SYK) by 8.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,165 shares of the medical technology company’s stock after selling 6,075 shares during the period. Stryker Corporation accounts for about 2.8% of Moreno Evelyn V’s investment portfolio, making the stock its 5th largest position. Moreno Evelyn V’s holdings in Stryker Corporation were worth $9,044,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the company. Bollard Group LLC boosted its stake in Stryker Corporation by 0.4% in the first quarter. Bollard Group LLC now owns 829 shares of the medical technology company’s stock valued at $109,000 after buying an additional 3 shares during the period. Baystate Wealth Management LLC boosted its stake in Stryker Corporation by 2.1% in the first quarter. Baystate Wealth Management LLC now owns 1,066 shares of the medical technology company’s stock valued at $139,000 after buying an additional 22 shares during the period. James Investment Research Inc. bought a new stake in Stryker Corporation during the second quarter valued at approximately $155,000. Guardian Life Insurance Co. of America boosted its stake in Stryker Corporation by 0.8% in the first quarter. Guardian Life Insurance Co. of America now owns 1,199 shares of the medical technology company’s stock valued at $158,000 after buying an additional 9 shares during the period. Finally, Assetmark Inc. boosted its stake in Stryker Corporation by 0.3% in the first quarter. Assetmark Inc. now owns 1,274 shares of the medical technology company’s stock valued at $168,000 after buying an additional 4 shares during the period. 73.99% of the stock is owned by institutional investors.
Shares of Stryker Corporation (SYK) traded up 0.19% during trading on Friday, hitting $144.18. 847,631 shares of the stock were exchanged. The stock has a market cap of $53.93 billion, a P/E ratio of 32.18 and a beta of 0.80. The firm’s 50 day moving average price is $143.71 and its 200-day moving average price is $135.51. Stryker Corporation has a 52 week low of $106.48 and a 52 week high of $148.84.
Stryker Corporation (NYSE:SYK) last issued its earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.02. The firm had revenue of $3.01 billion during the quarter, compared to analyst estimates of $2.98 billion. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The company’s quarterly revenue was up 6.1% on a year-over-year basis. During the same quarter last year, the business earned $1.39 earnings per share. On average, analysts predict that Stryker Corporation will post $6.50 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be given a dividend of $0.425 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.70 dividend on an annualized basis and a yield of 1.18%. Stryker Corporation’s dividend payout ratio is presently 37.95%.
Several analysts have recently commented on SYK shares. Cowen and Company set a $150.00 price target on shares of Stryker Corporation and gave the company an “outperform” rating in a research note on Wednesday, April 26th. Morgan Stanley reissued an “overweight” rating and set a $160.00 price target (up from $155.00) on shares of Stryker Corporation in a research note on Monday, July 10th. Cantor Fitzgerald started coverage on shares of Stryker Corporation in a research note on Thursday, June 29th. They set a “neutral” rating and a $153.00 price target on the stock. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target on the stock in a research note on Monday, July 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $140.00 price target (up from $135.00) on shares of Stryker Corporation in a research note on Wednesday, April 26th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. Stryker Corporation has an average rating of “Hold” and an average price target of $144.03.
In other Stryker Corporation news, insider Graham A. Mclean sold 1,124 shares of the stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the transaction, the insider now owns 8,983 shares in the company, valued at $1,313,853.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Floyd sold 19,305 shares of the stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total transaction of $2,790,730.80. The disclosure for this sale can be found here. Insiders have sold 32,810 shares of company stock valued at $4,754,958 in the last quarter. Company insiders own 7.40% of the company’s stock.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.